We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+2.22%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$563M
AUM Growth
+$168M
Cap. Flow
+$106M
Cap. Flow %
18.87%
Top 10 Hldgs %
78.85%
Holding
47
New
15
Increased
6
Reduced
2
Closed
11

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$43M
2
FBRX icon
Forte Biosciences
FBRX
+$22.5M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$16.5M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$14.7M
5
EDIT icon
Editas Medicine
EDIT
+$12.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$13.3M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$8.94M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$5.68M
4
XNCR icon
Xencor
XNCR
+$5.62M
5
KURA icon
Kura Oncology
KURA
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 76.97%
2 Miscellaneous 23.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
26
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.44M 0.43%
767,992
+385,992
+101% +$1.22M
ADVM
27
DELISTED
Adverum Biotechnologies
ADVM
$2.19M 0.39%
87,445
– –
NERV icon
28
Minerva Neurosciences
NERV
$231M
$1.98M 0.35%
+27,975
New +$1.81M
BHVN
29
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.75M 0.31%
+70,000
New +$1.61M
AGIO icon
30
Agios Pharmaceuticals
AGIO
$1.99B
$1.2M 0.21%
23,300
– –
CCXI
31
DELISTED
ChemoCentryx, Inc.
CCXI
$1.1M 0.2%
118,000
– –
BMY icon
32
Bristol-Myers Squibb
BMY
$136B
$951K 0.17%
17,060
– –
CLVS
33
DELISTED
Clovis Oncology, Inc.
CLVS
$936K 0.17%
+10,000
New +$612K
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$31.7B
$831K 0.15%
+10,425
New +$666K
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
$776K 0.14%
+15,000
New +$953K
PETX
36
DELISTED
Aratana Therapeutics, Inc.
PETX
$723K 0.13%
+100,000
New +$615K
ATRA icon
37
Atara Biotherapeutics
ATRA
$92.3M
– –
-17,392
Closed -$8.94M
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.74B
– –
-35,301
Closed -$484K
WVE icon
39
Wave Life Sciences
WVE
$993M
– –
-10,000
Closed -$275K
XNCR icon
40
Xencor
XNCR
$1.94B
– –
-234,813
Closed -$5.62M
SYRS
41
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-6,360
Closed -$1.01M
ARAV
42
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-16,667
Closed -$2.13M
JNCE
43
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-258,457
Closed -$5.68M
VIVE
44
DELISTED
VIVEVE MED INC
VIVE
– –
-250
Closed -$1.58M
FWP
45
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-718
Closed -$108K
CASC
46
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-103,800
Closed -$430K
OREX
47
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-117,726
Closed -$405K
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2017 Portfolio in Review

As of Q2 2017, EcoR1 Capital held 47 positions worth $563M, up 42% from $396M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2017, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was Forte Biosciences: 4,006 shares worth $18.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.3M trimmed.

  • EcoR1 Capital's largest Q2 2017 buy was Forte Biosciences: 4,006 shares worth $18.1M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2017, an estimated $43M increase.
  • EcoR1 Capital's biggest Q2 2017 reduction was Aclaris Therapeutics, cutting an estimated $13.3M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q2 2017, selling an estimated $8.94M.
  • EcoR1 Capital's ten largest holdings make up 79% of its $563M portfolio in Q2 2017.
  • EcoR1 Capital opened 15 new positions and closed 11 in Q2 2017.
  • EcoR1 Capital's portfolio value rose 42% quarter-over-quarter to $563M.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.